CPA
ATNM icon

Capital Performance Advisors’s Actinium Pharmaceuticals ATNM Stock Holding History

Capital Performance Advisors’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-437
Closed -$822 – 384
2024
Q3 		$822 Buy
+437
New +$1.73K ﹤0.01% 2009

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $25.4B AUM 38.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Capital Performance Advisors's ATNM Position: Q4 2024 in Review

Capital Performance Advisors sold out of Actinium Pharmaceuticals (ATNM) in Q4 2024, closing a stake of 437 shares — an estimated $822 sold.

Capital Performance Advisors first reported a position in ATNM in Q3 2024 and held it in 1 quarter. The position peaked at $822 in Q3 2024. 69 funds tracked by Wall St. Rank hold ATNM as of Q4 2024.

  • Capital Performance Advisors reported no remaining Actinium Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 437 Actinium Pharmaceuticals shares in Q4 2024, an estimated $822.
  • Capital Performance Advisors first reported a position in Actinium Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Actinium Pharmaceuticals position peaked at $822 in Q3 2024.
  • 69 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.